{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:41:36Z","timestamp":1781728896720,"version":"3.54.5"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) study (<jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> identifier: NCT00836017), a multicenter, prospective, observational registry, was designed to identify real-world practices and outcomes for patients with cervical dystonia (CD) treated with onabotulinumtoxinA (onabotA). This secondary analysis from CD PROBE aims to determine the impact of presentation subtype on onabotA utilization and CD severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>The study cohort includes those who completed all 3 treatments, 4 office visits, and had data recorded for all assessments. Patient outcomes were assessed with the Cervical Dystonia Impact Profile (CDIP-58), Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), and determination of CD severity. Treatment interval, dose, and adverse events (AEs) were also recorded. Data were stratified according to prior exposure to botulinum toxins (BoNTs) and analyzed with descriptive statistics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Torticollis was the most common presentation subtype in the study cohort (<jats:italic>N<\/jats:italic> = 350); the proportion of patients with torticollis was highest in those with severe disease. At each treatment, between 40.7 and 65.2% of those categorized as severe shifted to moderate or mild severity after treatment. Sustained improvements in CDIP-58 and TWSTRS were observed regardless of prior exposure to BoNTs. Dosing of onabotA generally increased from injection 1 to injection 3 and tended to be lower for patients na\u00efve to BoNT. Median time interval between injections for the study cohort was 94.0 to 97.5 days. The most common AEs (dysphagia, muscular weakness) and injection intervals were similar between na\u00efve vs. non-na\u00efve patients; there were no serious treatment-related AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This secondary cohort analysis from CD PROBE demonstrates that three repeat treatments with onabotA at intervals consistent with labeling attenuated disease severity and neck pain, resulting in sustained improvements in physician- and patient-reported outcomes. No new safety signals were identified.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.914486","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T13:09:20Z","timestamp":1656594560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE"],"prefix":"10.3389","volume":"13","author":[{"given":"Pinky","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Barbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksej","family":"Zuzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/mds.870060206","article-title":"Idiopathic cervical dystonia: clinical characteristics","volume":"6","author":"Chan","year":"1991","journal-title":"Mov Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S1474-4422(06)70547-6","article-title":"The diagnosis of dystonia","volume":"5","author":"Geyer","year":"2006","journal-title":"Lancet Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ene.13762","article-title":"Dystonia: diagnosis and management","volume":"26","author":"Albanese","year":"2019","journal-title":"Eur J Neurol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.170","article-title":"Descriptive epidemiology of cervical dystonia","volume":"3","author":"Defazio","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.parkreldis.2007.02.005","article-title":"Prevalence of cervical dystonia and spasmodic torticollis in the United States general population","volume":"13","author":"Jankovic","year":"2007","journal-title":"Parkinsonism Relat Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s004150070094","article-title":"A prevalence study of primary dystonia in eight European countries","volume":"247","year":"2000","journal-title":"J Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/mds.25244","article-title":"The prevalence of primary dystonia: a systematic review and meta-analysis","volume":"27","author":"Steeves","year":"2012","journal-title":"Mov Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1212\/01.WNL.0000026474.12594.0D","article-title":"The prevalence of primary dystonia in the general community","volume":"59","author":"Muller","year":"2002","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ene.13133","article-title":"Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland","volume":"24","author":"Williams","year":"2017","journal-title":"Eur J Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1017\/S0317167100031619","article-title":"Spasmodic torticollis\u2013review of 220 patients","volume":"18","author":"Rondot","year":"1991","journal-title":"Can J Neurol Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00415-014-7343-6","article-title":"Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy)","volume":"261","author":"Charles","year":"2014","journal-title":"J Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/mdc3.12238","article-title":"Impact of cervical dystonia on work productivity: an analysis from a patient registry","volume":"3","author":"Molho","year":"2016","journal-title":"Mov Disord Clin Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.3390\/toxins7062321","article-title":"Pain relief in cervical dystonia with botulinum toxin treatment","volume":"7","author":"Camargo","year":"2015","journal-title":"Toxins (Basel)."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1212\/WNL.41.7.1088","article-title":"Cervical dystonia: clinical findings and associated movement disorders","volume":"41","author":"Jankovic","year":"1991","journal-title":"Neurology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/mds.23709","article-title":"Nonmotor manifestations of dystonia: a systematic review","volume":"26","author":"Kuyper","year":"2011","journal-title":"Mov Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1080\/14737175.2021.1984230","article-title":"Pain in cervical dystonia: mechanisms, assessment and treatment","volume":"21","author":"Rosales","year":"2021","journal-title":"Expert Rev Neurother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/jnnp.72.5.608","article-title":"group Ec. What are the determinants of quality of life in people with cervical dystonia?","volume":"72","author":"Ben-Shlomo","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/mds.10127","article-title":"Epidemiological Study of Dystonia in Europe Collaborative G. Impact of cervical dystonia on quality of life","volume":"17","author":"Camfield","year":"2002","journal-title":"Mov Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fneur.2017.00035","article-title":"Clinical practice: evidence-based recommendations for the treatment of cervical dystonia with botulinum toxin","volume":"8","author":"Contarino","year":"2017","journal-title":"Front Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/toxins12050332","article-title":"FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia","volume":"12","author":"Spiegel","year":"2020","journal-title":"Toxins (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/brain\/121.4.547","article-title":"Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia","volume":"121","author":"Dauer","year":"1998","journal-title":"Brain."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.apmr.2003.10.012","article-title":"Phenol block for cervical dystonia: effects and side effects","volume":"85","author":"Takeuchi","year":"2004","journal-title":"Arch Phys Med Rehabil."},{"key":"B24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/(SICI)1097-4598(1997)6+<146::AID-MUS10>3.0.CO;2-4","article-title":"Botulinum toxin: chemistry, pharmacology, toxicity, and immunology","volume":"6","author":"Brin","year":"1997","journal-title":"Muscle Nerve Suppl"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1517\/14656560903426171","article-title":"Treatment strategies for dystonia","volume":"11","author":"Cloud","year":"2010","journal-title":"Expert Opin Pharmacother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: genetic, structural and mechanistic insights","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat Rev Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.parkreldis.2011.06.013","article-title":"Updates on the antinociceptive mechanism hypothesis of botulinum toxin A","volume":"1","author":"Aoki","year":"2011","journal-title":"Parkinsonism Relat Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/0333102414527648","article-title":"Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains","volume":"34","author":"Burstein","year":"2014","journal-title":"Cephalalgia."},{"key":"B29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/toxins6020592","article-title":"Time course analysis of the effects of botulinum neurotoxin type A on pain and vasomotor responses evoked by glutamate injection into human temporalis muscles","volume":"6","author":"da Silva","year":"2014","journal-title":"Toxins (Basel)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.3390\/toxins2122890","article-title":"Botulinum neurotoxin for pain management: insights from animal models","volume":"2","author":"Pavone","year":"2010","journal-title":"Toxins (Basel)."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of action of OnabotulinumtoxinA in chronic migraine: a narrative review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache."},{"key":"B32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1471-2377-11-140","article-title":"Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)","volume":"11","author":"Jankovic","year":"2011","journal-title":"BMC Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/jnnp-2012-303608","article-title":"Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia","volume":"84","author":"Dressler","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/papr.12408","article-title":"Neck Pain and Cervical Dystonia: Treatment Outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy)","volume":"16","author":"Charles","year":"2016","journal-title":"Pain Pract."},{"key":"B35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2014.12.030","article-title":"Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE)","volume":"349","author":"Jankovic","year":"2015","journal-title":"J Neurol Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: a consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov Disord."},{"key":"B37","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mds.870120414","article-title":"Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale","volume":"12","author":"Comella","year":"1997","journal-title":"Mov Disord."},{"key":"B38","first-page":"211","volume-title":"Clinical Assessments of Patients with Cervical Dystonia","author":"Consky","year":"1994"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1212\/01.WNL.0000142962.11881.26","article-title":"Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58)","volume":"63","author":"Cano","year":"2004","journal-title":"Neurology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.21724","article-title":"Myobloc\/Neurobloc European Cervical Dystonia Study G. Botulinum toxin type B vs type A in toxin-naive patients with cervical dystonia: Randomized, double-blind, noninferiority trial","volume":"23","author":"Pappert","year":"2008","journal-title":"Mov Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/WNF.0b013e3181c46f48","article-title":"A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia","volume":"33","author":"Quagliato","year":"2010","journal-title":"Clin Neuropharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/WNF.0b013e31826538c7","article-title":"Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia","volume":"35","author":"Charles","year":"2012","journal-title":"Clin Neuropharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"116413","DOI":"10.1016\/j.jns.2019.07.031","article-title":"Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study","volume":"405","author":"Dashtipour","year":"2019","journal-title":"J Neurol Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e2109","DOI":"10.1212\/WNL.0000000000009444","article-title":"Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy","volume":"94","author":"Walter","year":"2020","journal-title":"Neurology."},{"key":"B46","unstructured":"BOTOX (onabotulinumtoxinA) Label"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00702-021-02312-4","article-title":"Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity","volume":"128","author":"Dressler","year":"2021","journal-title":"J Neural Transm (Vienna)."},{"key":"B49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J Neurol Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov Disord."},{"key":"B51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jocn.2020.07.069","article-title":"Pain incidence in cervical dystonia is determined by the disease phenotype","volume":"79","author":"Marciniec","year":"2020","journal-title":"J Clin Neurosci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1017\/cjn.2020.275","article-title":"Improvement in Quality of Life with OnabotulinumtoxinA for Cervical Dystonia: POSTURe","volume":"48","author":"Petitclerc","year":"2021","journal-title":"Can J Neurol Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/jnnp.73.4.406","article-title":"Oropharyngeal swallowing in craniocervical dystonia","volume":"73","author":"Ertekin","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1212\/WNL.40.9.1443","article-title":"Swallowing function in patients with spasmodic torticollis","volume":"40","author":"Riski","year":"1990","journal-title":"Neurology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/BF02493443","article-title":"Swallowing in torticollis before and after rhizotomy","volume":"7","author":"Horner","year":"1992","journal-title":"Dysphagia."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1212\/WNL.42.7.1307","article-title":"Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings","volume":"42","author":"Comella","year":"1992","journal-title":"Neurology."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e776","DOI":"10.6061\/clinics\/2019\/e776","article-title":"Specific characteristics of the medical history of swallowing before and after application of botulinum toxin in patients with cervical dystonia","volume":"74","author":"Vilanova","year":"2019","journal-title":"Clinics (S\u00e3o Paulo)."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.914486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T13:09:26Z","timestamp":1656594566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.914486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":57,"alternative-id":["10.3389\/fneur.2022.914486"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.914486","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"article-number":"914486"}}